The pathophysiology of vascular obstruction in the sickle syndromes

Blood Reviews

Volumn 10, Issue 1, 1996, Pages 29-44

  Kaul, D K ^a   Fabry, M E ^a   Nagel, R L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; VASOACTIVE AGENT;

BLOOD VESSEL OCCLUSION; CHLORIDE TRANSPORT; ERYTHROCYTE; ERYTHROCYTE ADHESIVENESS; GENETIC EPISTASIS; HEMODYNAMICS; HUMAN; MICROCIRCULATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PLEIOTROPY; POLYMERIZATION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; VASCULAR ENDOTHELIUM;

EID: 0029988343     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90018-1     Document Type: Article

References (153)

1. Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood 1987; 70: 1245-1266.
2. Kaul DK, Fabry ME, Nagel RL. Erythrocytic and vascular factors influencing the microcirculatory behavior of blood in sickle cell anemia. [Review]. Ann NY Acad Sci 1989; 565: 316-326.
3. Nash GB, Johnson CS, Meiselman HJ. Rheologic impairment of sickle RBCs induced by repetitive cycles of deoxygenationreoxygenation. Blood 1988; 72: 539-545.
4. Mohandas N, Evans E. Rheological and adherence properties of sickle cells. Potential contribution to hematologic manifestations of the disease. [Review], Ann NY Acad Sci 1989; 565: 327-337.
5. Kurantsin Mills J, Lessin LS. Cellular and rheological factors contributing to sickle cell microvascular occlusion. Blood Cells 1986; 12: 249-270.
6. Chien S. The Benjamin W. Zweifach Award Lecture. Blood cell deformability and interactions: from molecules to micromechanics and microcirculation. Microvasc Res 1992; 44: 243-254.
7. Nagel RL, Fabry ME. The many pathophysiologies of sickle cell anemia. [Review]. Am J Hemat 1985; 20: 195-199.
8. S gene cluster haplotypes as genetic markers for severe disease expression. [Review]. Am J Dis Child 1993; 147: 1197-1202.
9. Pagnier J, Mears JG, Dunda-Belkhodja O et al. Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. Proc Natl Acad Sci USA 1984; 81: 1771-1773.
10. Bertles JF, Milner PFA. Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia. J Clin Invest 1968; 47: 1731-1741.
11. Fabry ME, Nagel RL. Heterogeneity of red cells in the sickler: a characteristic with practical clinical and pathophysiological implications. Blood Cells 1982; 8: 9-15.
12. Kaul DK, Fabry ME, Windisch P, Baez S, Nagel RL. Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic characteristics. J Clin Invest 1983; 72: 22-31.
13. Rodgers GP, Schechter AN, Noguchi CT. Cell heterogeneity in sickle cell disease: quantitation of the erythrocyte density profile. J Lab Clin Med 1985; 106: 30-37.
14. Steinberg MH. Genetic modulation of sickle cell anemia. [Review]. Proc Soc Exp Biol Med 1995; 209: 1-13.
15. Canessa M. Red cell volume related ion transport systems in hemoglobinopathies. Hematol Oncol Clin North Am 1991; 5: 495-516.
16. Joiner CH. Cation transport and volume regulation in sickle red blood cells. [Review]. Am J Physiol 1993; 264: C251-C270.
17. Embury SH. Alpha thalassemia. A modifier of sickle cell disease. Ann NY Acad Sci 1989; 565: 213-221.
18. Platt OS, Thorington BD, Brambilla DJ et al. Pain in sickle cell disease. Rates and risk factors [see comments], N Eng J Med 1991; 325: 11-16.
19. Castro O, Brambilla DJ, Thorington B et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84: 643-649.
20. Nagel RL, Fabry ME, Pagnier J et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. N Eng J Med 1985; 312: 880-884.
21. s gene. [Review]. Baillières Clinical Haematology 1992; 5: 331-365.
22. S-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol 1991; 28: 202-208.
23. Powars DR, Meiselman HJ, Fisher TC, Hiti A, Johnson C. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity. Am J Ped Hematol Oncol 1994; 16: 55-61.
24. Chang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, β-globin haplotypes, α-globin gene number, gender, and age. Blood 1995; 85: 1111-1117.
25. Steinberg MH, Hsu H, Nagel RL et al. Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. Am J Hemat 1995; 48: 175-181.
26. Nagel RL. Severity, pathobiology, epistatic effects, and genetic markers in sickle cell anemia. Semin Hematol 1991; 28: 180-201.
27. Nagel RL. Sickle cell anemia is a multigene disease: sickle painful crises, a case in point. [Review]. Am J Hemat 1993; 42: 96-101.
28. Cretegny I, Edelstein SJ. Double strand packing in hemoglobin S fibers. J Mol Biol 1993; 230: 733-738.
29. Nagel RL, Johnson J, Bookchin RM et al. Beta-chain contact sites in the haemoglobin S polymer. Nature 1980; 283: 832-834.
30. Wishner BC, Ward KB, Lattman EE, Love WE. Crystal structure of sickle-cell deoxyhemoglobin at 5 A resolution. J Mol Biol 1975; 98: 179-194.
31. Nagel RL, Bookchin RM, Johnson J et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA 1979; 76: 670-672.
32. Adachi K, Surrey S, Tamary H et al. Hb Shelby [beta] 131 (H9) Gln->Lys] in association with Hb S[beta 6(A3)Glu->Val]: characterization, stability, and effects on Hb S polymerization. Hemoglobin 1993; 17: 329-343.
33. Adachi K, Kim JY, Konitzer P, Asakura T, Saviola B, Surrey S. Effects of beta 6 amino acid hydrophobicity on stability and solubility of hemoglobin tetramers. FEBS Lett 1993; 315: 47-50.
34. Adachi K, Konitzer P, Surrey S. Role of gamma 87 Gln in the inhibition of hemoglobin S polymerization by hemoglobin F. J Biol Chem 1994; 269: 9562-9567.
35. Eaton WA, Hofrichter J. The biophysics of sickle cell hydroxyurea therapy. [Review]. Science 1995; 268: 1142-1143.
36. Noguchi CT, Rodgers GP, Schechter AN. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals. Prog Clin Biol Res 1987; 240: 381-391.
37. Billett HH, Kim K, Fabry ME, Nagel RL. The percentage of dense red cells does not predict incidence of sickle cell painful crisis. Blood 1986; 68: 301-303.
38. Bailey S, Higgs DR, Morris J, Serjeant GR. Is the painful crisis of sickle-cell disease due to sickling? [letter]. Lancet 1991; 337: 735.
39. Klug PP, Lessin LS. Microvascular blood flow of sickled erythrocytes. Blood Cells 1977; 3: 263-272.
40. LaCelle PL. Oxygen delivery to muscle cells during capillary occlusion by sickled erythrocytes. Blood Cells 1977; 3: 273-282.
41. Lipowsky HL, Sheikh NU, Katz DM. Intravital microscopy of capillary hemodynamics in sickle cell disease. J Clin Invest 1987; 80: 117-127.
42. Kaul DK, Xue H. Rate of deoxygenation and rheologic behavior of blood in sickle cell anemia. Blood 1991; 77: 1353-1361.
43. Hiruma H, Noguchi CT, Uyesaka N et al. Sickle cell rheology is determined by polymer fraction - not cell morphology. Am J Hemat 1995; 48: 19-28.
44. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest 1980; 65: 154-160.
45. Hebbel RP, Boogaerts MAB, Eaton JW, Steinberg MH. Erythrocyte adherence in sickle cell disorders. N Eng J Med 1980; 302: 992.
46. Wick TM, Moake JL, Udden MM, Eskin SG, Sears DA, Mclntire LV. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest 1987; 80: 905-910.
47. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci USA 1989; 86: 3356-3360.
48. Burns ER, Wilkinson WH, Nagel RL. Adherence properties of sickle erythrocytes in dynamic flow systems. J Lab Clin Med 1985; 105: 673-678.
49. Hoover R, Rubin R, Wise G, Warren R. Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures. Blood 1979; 54: 872-876.
50. Mohandas N, Evans E. Sickle erythrocyte adherence to vascular endothelium: morphologic correlates and the requirement for divalent cations and collagen-binding proteins. J Clin Invest 1985; 76: 1605-1612.
51. Barabino GA, McIntire LV, Eskin SG, Sears DA, Udden M. Endothelial cell interactions with sickle cell, sickle trait, mechanically injured, and normal erythrocytes under controlled flow. Blood 1987; 70: 152-157.
52. Wick TM, Moake JL, Udden MM, Mclntire LV. Unusually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am J Hemat 1993; 42: 284-292.
53. Kaul DK, Chen D, Zhan J. Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. Blood 1994; 83: 3006-3017.
54. Kaul DK, Sussman II, Tsai HM, Nagel RL. Anti-von Willebrand Factor antibodies inhibit and desmopressin enhances adhesion of SS cells to the endothelium in flow conditions. Clin Res 1989; 37: 546A.
55. Fabry ME, Rajanayagam V, Fine E et al. Modelling sickle cell vaso-occlusion in the rat leg: quantification of trapped sickle cells and correlation with P-31 metabolic and H-1 magnetic resonance imaging changes. Proc Natl Acad Sci USA 1988; 86: 3808-3812.
56. Fabry ME, Fine E, Rajanayagam V et al. Demonstration of endothelial adhesion of sickle cells in vivo: a distinct role for deformable sickle cell discocytes. Blood 1992; 79: 1602-1611.
57. Kaul DK, Fabry ME, Nagel RL. Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. Blood 1986; 68: 1162-1166.
58. Kaul DK, Chen D, Nagel RL, Tsai HM. Sickle cell adhesion to the endothelium in flow conditions: the role of von Willebrand factor. [Abstract] Blood 1991; 78: 369A.
59. Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyteendothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood 1993; 81: 2429-2438.
60. + sickle reticulocytes to endothelial cells. Blood 1992; 80: 2634-2642.
61. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993; 81: 2137-2143.
62. 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993; 82: 1891-1899.
63. 1 and gjycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993; 82: 3548-3555.
64. Barabino GA, Kasschau MR, Zhang B, Ewenstein BM, Golan DE. Adhesion of sickle RBCs to purified plasma proteins. [Abstract] Blood 1992; 80: 345A.
65. Prentice CRM, Forbes CD, Smith SM. Rise of factor VIII after exercise and adrenaline infusion measured by immunological and biological techniques. Thromb Res 1972; 1: 493-501.
66. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Brit J Hemat 1975; 30: 81-93.
67. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79: 117-123.
68. Handin RI, Wagner DD. Molecular and cellular biology of von Willebrand factor. [Review]. Prog Hemost Thromb 1989; 9: 233-259.
69. + associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J Clin Invest 1987; 79: 600-608.
70. Levine JD, Harlan JM, Harker LA, Joseph ML, Counts RB. Thrombin-mediated release of factor VIII antigen from human umbilical vein endothelial cells in culture. Blood 1982; 60: 531-534.
71. Richardson SG, Matthews KB, Stuart J, Geddes AM, Wilcox RM. Serial changes in coagulation and viscosity during sickle-cell crisis. Brit J Hemat 1979; 41: 95-103.
72. Mackie I, Bull H, Brozovic M. Altered Factor VIII complexes in sickle cell disease. Brit J Hemat 1980; 46: 499-502.
73. Klug PP, Kaye N, Jensen WN. Endothelial cell and vascular damage in the sickle cell disorders. Blood Cells 1982; 8: 175-184.
74. Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993; 154: 496-505.
75. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. [Review]. Am J Physiol 1990; 259: (1): C697-C708.
76. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987; 84: 6471-6475.
77. 3 for angiogenesis. Science 1994; 264: 569-571.
78. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol 1988; 107: (1): 2351-2361.
79. 3 and von Willebrand factor. In: Beuzard Y, Lubin B, Rosa J, eds. Sickle Cell Disease and Thalassemias: New Trends in Therapy. John Libby Eurotext Ltd, 1995: 497-500.
80. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood 1995; 85: 268-274.
81. Tanner MJ, Martin PG, High S. The complete amino acid sequence of the human erythrocyte membrane anion-transport protein deduced from the cDNA sequence. Biochem J 1988; 256: 703-712.
82. Kopito RR, Lodish HF. Primary structure and transmembrane orientation of the murine anion exchange protein. Nature 1985; 316: 234-238.
83. Low PS, Kannan R. Effect of hemoglobin denaturation on membrane structure and IgG binding: role in red cell aging. [Review], Prog Clin Biol Res 1989; 319: 525-546; : discussion 547-545.
84. Crandall I, Collins WE, Gysin J, Sherman IW. Synthetic peptides based on motifs present in human band 3 protein inhibit cytoadherence/sequestration of the malaria parasite Plasmodium falciparum. Proc Natl Acad Sci USA 1993; 90: 4703-4707.
85. Hebbel RP. Membrane associated iron. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press, 1994: 163-172.
86. Greaves DR, Fraser P, Vidai MA et al. A transgenic mouse model of sickle cell disorder. Nature 1990; 343: 183-185.
87. Ryan TM, Townes TM, Reilly MP, Asakura T, Palmiter RP, Behringer RR. Human sickle hemoglobin in transgenic mice. Science 1990; 247: 566-568.
88. Rubin EM, Witkowska HE, Spangler E et al. Hypoxia-induced in vivo sickling of transgenic mouse red cells. J Clin Invest 1991; 87: 639-647.
89. Trudel M, Saadane N, Garel M et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J 1991; 10: 3157-3168.
90. Fabry ME, Costantini F, Pachnis A et al. High expression of human beta S-and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci USA 1992; 89: 12155-12159.
91. s and α-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci USA 1992; 89: 12150-12154.
92. Fabry ME. Transgenic animal models of sickle cell disease. [Review]. Experientia 1993; 49: 28-36.
93. Nagel RL. Lessons from transgenic mouse lines expressing sickle hemoglobin. [Review]. Proc Soc Exp Biol Med 1994; 205: 274-281.
94. Skow LC, Burkhart BA. Johnson FM et al. A mouse model for beta-thalassemia. Cell 1983; 34: 1043-1052.
95. Lutty GA, McLeod DS, Pachnis A, Costantini F, Fabry ME, Nagel RL. Retinal and choroidal neovascularization in a transgenic mouse model of sickle cell disease. Am J Path 1994; 145: 490-497.
96. Rhoda MD, Domenget C, Vidaud M et al. Mouse alpha chains inhibit polymerization of hemoglobin induced by human beta S or beta S Antilles chains. Biochim Biophys Acta 1988; 952: 208-212.
97. Roy RP, Nagel RL, Acharya AS. Molecular basis of the inhibition of beta s-chain-dependent polymerization by mouse alpha-chain. Semisynthesis of chimeras of human and mouse alpha-chains. J Biol Chem 1993; 268: 16406-16412.
98. Trudel M, De Paepe ME, Chretien N et al. Sickle cell disease of transgenic SAD mice. Blood 1994; 84: 3189-3197.
99. Fabry ME, Sengupta A, Suzuka SM et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood 1995; 86: 2419-2428.
100. Kaul DK, Fabry ME, Costantini F, Rubin EM, Nagel RL. In vivo demonstration of red cell-endothelial interactions, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96: 2845-2853.
101. Zweifach BW, Lipowsky HH. Pressure-Flow relations in blood and lymph microcirculation. In: Renkin EM, Michen CC, eds. Cardiovascular System. Bethesda MD: Am Physiol Soc, 1984: 251-308.
102. Swain DP, Pittman RN. Oxygen exchange in the microcirculation of hamster retractor muscle. Am J Physiol 1989; 256: (2): H247-H255.
103. Duling BR, Berne RM. Longitudinal gradients in periarteriolar oxygen tension. A possible mechanism for the participation of oxygen in local regulation of blood flow. Circ Res 1970; 27: 669-678.
104. Anderson GL, Miller FN, Xiu RJ. Inhibition of histamine-induced protein leakage in rat skeletal muscle by blockade of prostaglandin synthesis. Microvasc Res 1984; 28: 51-61.
105. Fox JR, Wayland H. Interstitial diffusion of macromolecules in the rat mesentery. Microvasc Res 1979; 18: 255-276.
106. Clark MR, Mohandas N, Shohet SB. Deformability of oxygenated irreversibly sickled cells. J Clin Invest 1980; 65: 189-196.
107. Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochim Biophys Acta 1958; 30: 653.
108. Brugnara C, Bunn HF, Tosteson DC. Regulation of erythrocyte cation and water content in sickle cell anemia. Science 1986; 232: 388-390.
109. Canessa M, Spalvins A, Nagel RL. Volume-dependent and NEM-stimulated K:Cl-transport is elevated in oxygenated SS, SC, and CC human red cells. FEBS Lett 1986; 200: 197-202.
110. Bookchin RM, Ortiz OE, Lew VL. Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. J Clin Invest 1991; 87: 113-124.
111. Fabry ME, Romero J, Buchanan ID et al. Rapid increase in red blood cell density driven by K: Cl cotransport in a subset of sickle cell anemia reticulocytes and discocytes. Blood 1991; 78: 217-225.
112. + efflux and forms dense cells. [Abstract] Clin Res 1993; 41: 307A.
113. + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives [see comments]. J Clin Invest 1993; 92: 520-526.
114. + transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J Clin Invest 1994; 93: 1670-1676.
115. Katusic ZS, Consentino F. Nitric oxide synthase: from molecular biology to cerebrovascular physiology. NIPS 1994; 9: 64-67.
116. Mosseri M, Bartlett-Pandite AN, Wenc K, Isner JM, Weinstein R. Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J 1993; 126: 338-346.
117. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 and nitric oxide synthase genes in human endothelial cells. [Abstract] Blood 1994; 81: 264A.
118. Bank N, Aynedjian HS, Qui J, Fabry ME, Nagel RL. Increased abundance of nitric oxide synthase (NOS) in kidneys of transgenic mice. [Abstract] Clin Res 1994; 42(2): 265A.
119. Clark IA, Rockett KA, Cowden WB. Proposed link between cytokines, nitric oxide, and human cerebral malaria. Paras Today 1991; 7: 205-207.
120. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
121. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW, Bonner RF. Periodic microcirculatory flow in patients with sickle-cell disease. N Eng J Med 1984; 311: 1534-1538.
122. Sowemimo-Coker SO, Meiselman HJ, Francis RB Jr. Increased circulating endothelial cells in sickle cell crisis. Am J Hemat 1989; 31: 263-265.
123. Sowemimo-Coker SO, Haywood LJ, Meiselman HJ, Francis RB Jr. Effects of normal and sickle erythrocytes on prostacyclin release by perfused human umbilical cord veins. Am J Hemat 1992; 40: 276-282.
124. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 1995; 96: 1145-1151.
125. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991; 88: 1054-1057.
126. Serjeant GR, Ceulaer CD, Lethbridge R, Morris J, Singhal A, Thomas PW. The painful crisis of homozygous sickle cell disease: clinical features. Brit J Hemat 1994; 87: 586-591.
127. Lutty GA, McLeod DS, Fabry ME, Costantini FM, Nagel RL. Comparison of retinopathies in human SC sickle cell disease and in a transgenic mouse model of sickle cell disease. [Abstract] Blood 1992; 81: 11.
128. Bank N, Fabry ME, Costantini F, Aynedjian HS, Nagel RL, Renal function in sickle cell transgenic mice. The effect of age, percent HbSm and cyclic hypoxia. [Abstract] Clin Res 1993; 41(2): 285A.
129. De Paepe ME, Trudel M. The transgenic SAD mouse: a model of human sickle cell glomerulopathy. Kidney Int 1994; 46: 1337-1345.
130. Aldrich TK, Dhuper S, Patwa NS et al. Pulmonary entrapment of sickle cells: the role of regional alveolar hypoxia. J Appl Physiol 1995; in press.
131. Greenberg MS, Kass EH. Studies on the destruction of red blood cells. XIII. Observations on the role of pH in pathogenesis and treatment of painful crisis in sickle cell disease. Arch Intern Med 1958; 101: 355-363.
132. Marsden PD, Shah KK. Artificially induced edema in sickle cell anemia. J Trop Med Hyg 1964; 67: 31.
133. Fabry ME, Benjamin L, Lawrence C, Nagel RL. An objective sign in painful crisis in sickle cell anemia: the concomitant reduction of high density red cells. Blood 1984; 64: 559-563.
134. Lawrence C, Fabry ME, Nagel RL. Red cell distribution width parallels dense red cell disappearance during painful crises in sickle cell anemia. J Lab Clin Med 1985; 105: 706-710.
135. Billett HH, Fabry ME, Nagel RL. Hemoglobin distribution width: a rapid assessment of dense red cells in the steady state and during painful crisis in sickle cell anemia. J Lab Clin Med 1988; 112: 339-344.
136. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992; 79: 2154-2163.
137. Kaul DK, Nagel RL, Baez S. Pressure effects on the flow behavior of sickle (HbSS) red cells in isolated (ex-vivo) microvascular system. Microvasc Res 1983; 26: 170-181.
138. Serjeant GR, Chalmers RM. Current concerns in haematology. 1. Is the painful crisis of sickle cell disease a 'steal' syndrome? [Review] J Clin Path 1990; 43: 789-791.
139. Roddie IC, ed. Circulation to skin and adipose tissue. In: Handbook of Physiology. Bethesda MD; American Physiological Society, 1960.
140. Benjamin LJ, Swinson GI. Parenteral anti-inflamatory analgesics (NSAIDS) as an adjunct or alternative to narcotics in the treatment of acute vasocclusive sickle pain: Ketorolac tromethamine usage in the Day Hospital. 17th Annual Meeting of the National Sickle Cell Disease Program (1992), Nashville, TN, USA.
141. Becton DL, Raymond L, Thompson C, Berry DH. Acutephase reactants in sickle cell disease. J Pediatr 1989; 115: 99-102.
142. Padmos MA, Roberts GT, Sackey K et al. Two different forms of homozygous sickle cell disease occur in Saudi Arabia. Brit J Hemat 1991; 79: 93-98.
143. Akinola NO, Stevens SM, Franklin IM, Nash GB, Stuart J. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Path 1992; 45: 902-906.
144. Singhal A, Doherty JF, Raynes JG et al. Is there an acutephase response in steady-state sickle cell disease? [see comments] Lancet 1993; 341: 651-653.
145. Gill FM, Sleeper LA, Weiner SJ et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. [Review] Blood 1995; 86: 776-783.
146. Powars DR, Schroeder WA, Weiss JN, Chan LS, Azen SP. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia. J Clin Invest 1980; 65: 732-740.
147. Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch Intern Med 1987; 147: 1231-1234.
148. Harkness DR, Roth S. Clinical evaluation of cyanate in sickle cell anemia. [Review] Prog Hemat 1975; 9: 157-184.
149. Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia [see comments] N Eng J Med 1995; 332: 1317-1322.
150. Bridges K, Barabino GA, Brugnara C et al. Early changes in sickle RBC parameters in patients treated with hydroxyurea. The 19th Annual Meeting of the National Sickle Cell Disease Program (1994), New York, NY, USA.
151. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994; 83: 553-560.
152. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Predicting therapeutic efficacy for sickle cell anemia. Prog Clin Biol Res 1987; 251: 497-505.
153. Fabry ME, Mears JG, Patel P et al. Dense cells in sickle cell anemia: the effects of gene interaction. Blood 1984; 64: 1042-1046.